Ποια είναι η τιμή για CARsgen Therapeutics Holdings Limited (2171)

Η τιμή για CARsgen Therapeutics Holdings Limited (2171) είναι $1.72

Ποια είναι η κεφαλαιοποίηση αγοράς για CARsgen Therapeutics Holdings Limited (2171)

Η κεφαλαιοποίηση αγοράς για CARsgen Therapeutics Holdings Limited (2171) είναι $981.92M

CARsgen Therapeutics Holdings Limited (2171) Διαίρεση Μετοχών

CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.